The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells

被引:25
作者
Baptiste N. [1 ]
Friedlander P. [1 ]
Chen X. [1 ]
Prives C. [1 ]
机构
[1] Department of Biological Sciences, Columbia University, New York
关键词
Anti-neoplastics; Apoptosis; p53; Proline-rich domain;
D O I
10.1038/sj.onc.1205015
中图分类号
学科分类号
摘要
In some cell types either DNA damage or p53 expression leads to minimal cell death, while combining the two leads to a strong apoptotic response. To further understand features of p53 that contribute to this increased cell death we used clones of H1299 cells that express wild-type or several mutant forms of p53 under a tetracycline-regulated promoter. In these cells the induction of wild-type p53 leads to significant apoptosis only when combined with exposure to a number of chemotherapeutic agents. A common target of p53, p21, is itself not sufficient to cause apoptosis in the presence of these chemotherapeutic compounds. Many agents also effectively increase cell death when a transcriptionally-defective p53, p53[gln22ser23], is induced, although a dramatic exception is treatment with 5-FU, which strongly cooperates with wild-type but not p53[gln22ser23]. Our results with 5-FU thus show that genetically separable functions of p53 are involved in its ability to respond to DNA-damaging agents to induce apoptosis. Notably as well, deleting the C-terminal 30 amino acids of p53 does not affect this cooperative effect with DNA-damaging agents. By contrast, a p53 mutant lacking the PXXP-domain between residues 60-90, while at least partially transcriptionally-competent, cannot be rendered apoptotic by any compounds that we tested. Thus the PXXP domain provides an essential component of the ability of p53 to respond to DNA-damaging agents to cause cell death.
引用
收藏
页码:9 / 21
页数:12
相关论文
共 115 条
  • [21] Chen X., Ko L.J., Jayaraman L., Prives C., Genes Dev., 10, pp. 2438-2451, (1996)
  • [22] Chiou S.K., Rao L., White E., Mol. Cell. Biol., 14, pp. 2556-2563, (1994)
  • [23] D'Arpa P., Liu L.F., Biochim. Biophys. Acta, 989, pp. 163-177, (1989)
  • [24] Darzynkiewicz Z., Bruno S., Del Bino G., Traganos F., Ann. NY Acad. Sci., 803, pp. 93-100, (1996)
  • [25] Degtyareva N., Subramanian D., Griffith J.D., J. Biol. Chem., 20, (2000)
  • [26] El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer W.E., Kinzler K.W., Vogelstein B., Cell, 75, pp. 817-825, (1993)
  • [27] El-Deiry W.S., Semin. Cancer Biol., 8, pp. 345-357, (1998)
  • [28] Engelborghs Y., Eur. Biophys. J., 27, pp. 437-445, (1998)
  • [29] Fadok V.A., Voelker D.R., Campbell P.A., Cohen J.J., Bratton D.L., Henson P.M., J. Immunol., 148, pp. 2207-2216, (1992)
  • [30] Ferreira C.G., Tolis C., Giaccone G., Ann. Oncol., 10, pp. 1011-1021, (1999)